Nanomedicine

NUCRYST Pharmaceuticals announces 2007 second quarter results

Published in Drug Week, August 24th, 2007

NUCRYST Pharmaceuticals Corp. announced for the quarter ended June 30, 2007, it recorded a net loss of $3.0 million, or 16 cents per share on revenues of $6.1 million, compared to a net loss of $3.9 million, or 21 cents per share on revenues of $6.2 million recorded in the same period last year.

At June 30, 2007, NUCRYST had $20.2 million in cash and short term investments. Further financial information follows at the end of the release.

"NUCRYST continued to advance our product development strategy in the first half of 2007," said Scott H. Gillis, President & CEO, NUCRYST Pharmaceuticals. "We continued with our preclinical work for gastroenterology...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2007-08-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry